{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,29]],"date-time":"2026-08-29T04:14:12Z","timestamp":1787976852447,"version":"build-2784847793"},"reference-count":166,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2025,3,1]],"date-time":"2025-03-01T00:00:00Z","timestamp":1740787200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,3,1]],"date-time":"2025-03-01T00:00:00Z","timestamp":1740787200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,2,3]],"date-time":"2025-02-03T00:00:00Z","timestamp":1738540800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100004329","name":"Slovenian Research and Innovation Agency","doi-asserted-by":"publisher","award":["P1-0208"],"award-info":[{"award-number":["P1-0208"]}],"id":[{"id":"10.13039\/501100004329","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004329","name":"Slovenian Research and Innovation Agency","doi-asserted-by":"publisher","award":["I0- 0022"],"award-info":[{"award-number":["I0- 0022"]}],"id":[{"id":"10.13039\/501100004329","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004329","name":"Slovenian Research and Innovation Agency","doi-asserted-by":"publisher","award":["I0-E011"],"award-info":[{"award-number":["I0-E011"]}],"id":[{"id":"10.13039\/501100004329","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.fr","clinicalkey.jp","clinicalkey.es","clinicalkey.com.au","clinicalkey.com","em-consulte.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Biomedicine &amp; Pharmacotherapy"],"published-print":{"date-parts":[[2025,3]]},"DOI":"10.1016\/j.biopha.2025.117893","type":"journal-article","created":{"date-parts":[[2025,2,8]],"date-time":"2025-02-08T22:52:15Z","timestamp":1739055135000},"page":"117893","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":9,"special_numbering":"C","title":["Thiopurine S-methyltransferase \u2013 An important intersection of drug-drug interactions in thiopurine treatment"],"prefix":"10.1016","volume":"184","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-5586-8913","authenticated-orcid":false,"given":"Dunja","family":"Urban\u010di\u010d","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marko","family":"Juki\u010d","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alenka","family":"\u0160mid","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stanislav","family":"Gobec","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Janez","family":"Jazbec","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7459-3502","authenticated-orcid":false,"given":"Irena","family":"Mlinari\u010d-Ra\u0161\u010dan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.biopha.2025.117893_bib1","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1111\/j.1749-6632.1954.tb40008.x","article-title":"The chemistry and biochemistry of purine analogs","volume":"60","author":"Hitchings","year":"1954","journal-title":"Ann. N. Y. Acad. Sci."},{"key":"10.1016\/j.biopha.2025.117893_bib2","doi-asserted-by":"crossref","first-page":"965","DOI":"10.1182\/blood.V8.11.965.965","article-title":"Clinical evaluation of a new antimetabolite, 6-mercaptopurine, in the treatment of leukemia and allied diseases","volume":"8","author":"Burchenal","year":"1953","journal-title":"Blood"},{"key":"10.1016\/j.biopha.2025.117893_bib3","first-page":"1207","article-title":"RElationship Between Metabolic Fates And Antitumor Activities Of Thiopurines","volume":"23","author":"Elion","year":"1963","journal-title":"Cancer Res"},{"key":"10.1016\/j.biopha.2025.117893_bib4","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1038\/clpt.1987.4","article-title":"Thiopurine pharmacogenetics in leukemia: correlation of erythrocyte thiopurine methyltransferase activity and 6-thioguanine nucleotide concentrations","volume":"41","author":"Lennard","year":"1987","journal-title":"Clin. Pharmacol. Ther."},{"key":"10.1016\/j.biopha.2025.117893_bib5","doi-asserted-by":"crossref","first-page":"1078","DOI":"10.1016\/S0021-9258(18)81262-5","article-title":"Metabolism of thiopyrimidines and thiopurines. S-Methylation with S-adenosylmethionine transmethylase and catabolism in mammalian tissues","volume":"238","author":"REMY","year":"1963","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.biopha.2025.117893_bib6","doi-asserted-by":"crossref","first-page":"471","DOI":"10.1016\/S0026-895X(25)14466-0","article-title":"Thiopurine methyltransferase. Aromatic thiol substrates and inhibition by benzoic acid derivatives","volume":"24","author":"Woodson","year":"1983","journal-title":"Mol. Pharmacol."},{"key":"10.1016\/j.biopha.2025.117893_bib7","doi-asserted-by":"crossref","first-page":"969","DOI":"10.1016\/j.bcp.2012.01.010","article-title":"Post-translational stabilization of thiopurine S-methyltransferase by S-adenosyl-L-methionine reveals regulation of TPMT*1 and *3C allozymes","volume":"83","author":"Milek","year":"2012","journal-title":"Biochem. Pharmacol."},{"key":"10.1016\/j.biopha.2025.117893_bib8","doi-asserted-by":"crossref","first-page":"182","DOI":"10.1016\/j.bbagen.2018.10.002","article-title":"Methylation of selenocysteine catalysed by thiopurine S-methyltransferase","volume":"1863","author":"Urban\u010di\u010d","year":"2019","journal-title":"Biochim Biophys. Acta Gen. Subj."},{"key":"10.1016\/j.biopha.2025.117893_bib9","doi-asserted-by":"crossref","first-page":"808","DOI":"10.1002\/cpt.2637","article-title":"Molybdenum cofactor catabolism unravels the physiological role of the drug metabolizing enzyme thiopurine s-methyltransferase","volume":"112","author":"Pristup","year":"2022","journal-title":"Clin. Pharm. Ther."},{"key":"10.1016\/j.biopha.2025.117893_bib10","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejps.2023.106616","article-title":"Transcriptome analysis reveals involvement of thiopurine S-methyltransferase in oxidation-reduction processes","volume":"192","author":"\u0160mid","year":"2024","journal-title":"Eur. J. Pharm. Sci."},{"key":"10.1016\/j.biopha.2025.117893_bib11","doi-asserted-by":"crossref","first-page":"198","DOI":"10.1002\/prot.21272","article-title":"Structural basis of allele variation of human thiopurine-S-methyltransferase","volume":"67","author":"Wu","year":"2007","journal-title":"Proteins"},{"key":"10.1016\/j.biopha.2025.117893_bib12","article-title":"Structural genomics consortium (SGC)","author":"Battaile","year":"2005","journal-title":"Cryst. Struct. thiopurine S-methyltransferase Homo Sapiens"},{"key":"10.1016\/j.biopha.2025.117893_bib13","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1016\/0140-6736(90)91745-V","article-title":"Genetic variation in response to 6-mercaptopurine for childhood acute lymphoblastic leukaemia","volume":"336","author":"Lennard","year":"1990","journal-title":"Lancet"},{"key":"10.1016\/j.biopha.2025.117893_bib14","doi-asserted-by":"crossref","first-page":"971","DOI":"10.1038\/leu.2008.317","article-title":"Heterozygosity at the TPMT gene locus, augmented by mutated MTHFR gene, predisposes to 6-MP related toxicities in childhood ALL patients","volume":"23","author":"Karas-Kuzelicki","year":"2009","journal-title":"Leukemia"},{"key":"10.1016\/j.biopha.2025.117893_bib15","doi-asserted-by":"crossref","first-page":"1743","DOI":"10.1046\/j.1365-2036.2002.01353.x","article-title":"Thiopurine methyltransferase activity and the use of azathioprine in inflammatory bowel disease","volume":"16","author":"Ansari","year":"2002","journal-title":"Aliment. Pharmacol. Ther."},{"key":"10.1016\/j.biopha.2025.117893_bib16","doi-asserted-by":"crossref","first-page":"279","DOI":"10.1097\/00008571-199608000-00001","article-title":"Genetic polymorphism of thiopurine S-methyltransferase: clinical importance and molecular mechanisms","volume":"6","author":"Krynetski","year":"1996","journal-title":"Pharmacogenetics"},{"key":"10.1016\/j.biopha.2025.117893_bib17","doi-asserted-by":"crossref","first-page":"429","DOI":"10.1097\/00008571-200208000-00003","article-title":"Azathioprine therapy and adverse drug reactions in patients with inflammatory bowel disease: impact of thiopurine S-methyltransferase polymorphism","volume":"12","author":"Schwab","year":"2002","journal-title":"Pharmacogenetics"},{"key":"10.1016\/j.biopha.2025.117893_bib18","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1111\/bjh.13240","article-title":"Thiopurine dose intensity and treatment outcome in childhood lymphoblastic leukaemia: the influence of thiopurine methyltransferase pharmacogenetics","volume":"169","author":"Lennard","year":"2015","journal-title":"Br. J. Haematol."},{"key":"10.1016\/j.biopha.2025.117893_bib19","doi-asserted-by":"crossref","first-page":"324","DOI":"10.1038\/clpt.2013.4","article-title":"Clinical Pharmacogenetics Implementation Consortium, Clinical pharmacogenetics implementation consortium guidelines for thiopurine methyltransferase genotype and thiopurine dosing: 2013 update","volume":"93","author":"Relling","year":"2013","journal-title":"Clin. Pharmacol. Ther."},{"key":"10.1016\/j.biopha.2025.117893_bib20","doi-asserted-by":"crossref","first-page":"606","DOI":"10.1038\/leu.2017.265","article-title":"Results of NOPHO ALL2008 treatment for patients aged 1-45 years with acute lymphoblastic leukemia","volume":"32","author":"Toft","year":"2018","journal-title":"Leukemia"},{"key":"10.1016\/j.biopha.2025.117893_bib21","doi-asserted-by":"crossref","first-page":"6216","DOI":"10.1021\/bi800102x","article-title":"Structural basis of substrate recognition in thiopurine s-methyltransferase","volume":"47","author":"Peng","year":"2008","journal-title":"Biochemistry"},{"key":"10.1016\/j.biopha.2025.117893_bib22","unstructured":"TPMT thiopurine S-methyltransferase [Homo sapiens (human)] - Gene - NCBI, (n.d.). \u3008https:\/\/www.ncbi.nlm.nih.gov\/gene\/7172\u3009 (accessed July 30, 2024)."},{"key":"10.1016\/j.biopha.2025.117893_bib23","doi-asserted-by":"crossref","first-page":"510","DOI":"10.1046\/j.1432-1327.1998.2560510.x","article-title":"Functional characterization of the human thiopurine S-methyltransferase (TPMT) gene promoter","volume":"256","author":"Fessing","year":"1998","journal-title":"Eur. J. Biochem."},{"key":"10.1016\/j.biopha.2025.117893_bib24","unstructured":"TPMT nomenclature committee, (n.d.). \u3008https:\/\/liu.se\/en\/research\/tpmt-nomenclature-committee\u3009 (accessed July 30, 2024)."},{"key":"10.1016\/j.biopha.2025.117893_bib25","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1016\/j.bcp.2019.04.020","article-title":"Comprehensive study of thiopurine methyltransferase genotype, phenotype, and genotype-phenotype discrepancies in Sweden","volume":"164","author":"Zimdahl Kahlin","year":"2019","journal-title":"Biochem. Pharmacol."},{"key":"10.1016\/j.biopha.2025.117893_bib26","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1089\/dna.1996.15.17","article-title":"Thiopurine methyltransferase pharmacogenetics: human gene cloning and characterization of a common polymorphism","volume":"15","author":"Szumlanski","year":"1996","journal-title":"DNA Cell Biol."},{"key":"10.1016\/j.biopha.2025.117893_bib27","first-page":"694","article-title":"Thiopurine S-methyltransferase deficiency: two nucleotide transitions define the most prevalent mutant allele associated with loss of catalytic activity in Caucasians","volume":"58","author":"Tai","year":"1996","journal-title":"Am. J. Hum. Genet."},{"key":"10.1016\/j.biopha.2025.117893_bib28","doi-asserted-by":"crossref","first-page":"949","DOI":"10.1073\/pnas.92.4.949","article-title":"A single point mutation leading to loss of catalytic activity in human thiopurine S-methyltransferase","volume":"92","author":"Krynetski","year":"1995","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.biopha.2025.117893_bib29","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1159\/000093278","article-title":"Thiopurine S-methyltransferase pharmacogenetics: genotype to phenotype correlation in the Slovenian population","volume":"77","author":"Milek","year":"2006","journal-title":"Pharmacology"},{"key":"10.1016\/j.biopha.2025.117893_bib30","first-page":"189","article-title":"Characterization of a variable number tandem repeat region in the thiopurine S-methyltransferase gene promoter","volume":"9","author":"Spire-Vayron de la Moureyre","year":"1999","journal-title":"Pharmacogenetics"},{"key":"10.1016\/j.biopha.2025.117893_bib31","doi-asserted-by":"crossref","first-page":"172","DOI":"10.1007\/s00439-002-0784-5","article-title":"Evolution of a VNTR located within the promoter region of the thiopurine methyltransferase gene: inferences from population and sequence data","volume":"111","author":"Alves","year":"2002","journal-title":"Hum. Genet."},{"key":"10.1016\/j.biopha.2025.117893_bib32","doi-asserted-by":"crossref","first-page":"547","DOI":"10.2217\/pgs.10.7","article-title":"Functional analysis of the role of the TPMT gene promoter VNTR polymorphism in TPMT gene transcription","volume":"11","author":"Zukic","year":"2010","journal-title":"Pharmacogenomics"},{"key":"10.1016\/j.biopha.2025.117893_bib33","doi-asserted-by":"crossref","first-page":"1311","DOI":"10.2217\/pgs-2018-0123","article-title":"Novel motif of variable number of tandem repeats in TPMT promoter region and evolutionary association of variable number of tandem repeats with TPMT*3 alleles","volume":"19","author":"Urban\u010di\u010d","year":"2018","journal-title":"Pharmacogenomics"},{"key":"10.1016\/j.biopha.2025.117893_bib34","doi-asserted-by":"crossref","first-page":"1701","DOI":"10.2217\/pgs.15.109","article-title":"TPMT gene expression is increased during maintenance therapy in childhood acute lymphoblastic leukemia patients in a TPMT gene promoter variable number of tandem repeat-dependent manner","volume":"16","author":"Kotur","year":"2015","journal-title":"Pharmacogenomics"},{"key":"10.1016\/j.biopha.2025.117893_bib35","first-page":"651","article-title":"Mercaptopurine pharmacogenetics: monogenic inheritance of erythrocyte thiopurine methyltransferase activity","volume":"32","author":"Weinshilboum","year":"1980","journal-title":"Am. J. Hum. Genet."},{"key":"10.1016\/j.biopha.2025.117893_bib36","doi-asserted-by":"crossref","first-page":"684","DOI":"10.1002\/cpt.540","article-title":"Polymorphic variation in TPMT is the principal determinant of TPMT phenotype: A meta-analysis of three genome-wide association studies","volume":"101","author":"Tamm","year":"2017","journal-title":"Clin. Pharmacol. Ther."},{"key":"10.1016\/j.biopha.2025.117893_bib37","doi-asserted-by":"crossref","first-page":"971","DOI":"10.1038\/leu.2008.317","article-title":"Heterozygosity at the TPMT gene locus, augmented by mutated MTHFR gene, predisposes to 6-MP related toxicities in childhood ALL patients","volume":"23","author":"Karas-Kuzelicki","year":"2009","journal-title":"Leukemia"},{"key":"10.1016\/j.biopha.2025.117893_bib38","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1016\/j.clinbiochem.2009.09.003","article-title":"MTHFR and TYMS genotypes influence TPMT activity and its differential modulation in males and females","volume":"43","author":"Karas-Kuzelicki","year":"2010","journal-title":"Clin. Biochem."},{"key":"10.1016\/j.biopha.2025.117893_bib39","doi-asserted-by":"crossref","first-page":"1845","DOI":"10.1016\/j.bcp.2009.03.006","article-title":"S-adenosylmethionine regulates thiopurine methyltransferase activity and decreases 6-mercaptopurine cytotoxicity in MOLT lymphoblasts","volume":"77","author":"Milek","year":"2009","journal-title":"Biochem. Pharmacol."},{"key":"10.1016\/j.biopha.2025.117893_bib40","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1016\/0009-8981(78)90311-X","article-title":"Human erythrocyte thiopurine methyltransferase: radiochemical microassay and biochemical properties","volume":"85","author":"Weinshilboum","year":"1978","journal-title":"Clin. Chim. Acta"},{"key":"10.1016\/j.biopha.2025.117893_bib41","doi-asserted-by":"crossref","first-page":"1437","DOI":"10.2217\/pgs.14.84","article-title":"From pharmacogenetics to pharmacometabolomics: SAM modulates TPMT activity","volume":"15","author":"Karas-Ku\u017eeli\u010dki","year":"2014","journal-title":"Pharmacogenomics"},{"key":"10.1016\/j.biopha.2025.117893_bib42","doi-asserted-by":"crossref","first-page":"12198","DOI":"10.1021\/bi0492556","article-title":"Consequences of binding an S-adenosylmethionine analogue on the structure and dynamics of the thiopurine methyltransferase protein backbone","volume":"43","author":"Scheuermann","year":"2004","journal-title":"Biochemistry"},{"key":"10.1016\/j.biopha.2025.117893_bib43","doi-asserted-by":"crossref","first-page":"555","DOI":"10.1097\/00008571-200309000-00004","article-title":"Thiopurine S-methyltransferase pharmacogenetics: chaperone protein association and allozyme degradation","volume":"13","author":"Wang","year":"2003","journal-title":"Pharmacogenetics"},{"key":"10.1016\/j.biopha.2025.117893_bib44","article-title":"Thiopurine S-Methyltransferase","author":"Peng","year":"2008","journal-title":"Mus. musculus"},{"key":"10.1016\/j.biopha.2025.117893_bib45","doi-asserted-by":"crossref","first-page":"819","DOI":"10.1016\/0006-2952(83)90582-8","article-title":"Human kidney thiopurine methyltransferase. Purification and biochemical properties","volume":"32","author":"Woodson","year":"1983","journal-title":"Biochem. Pharmacol."},{"key":"10.1016\/j.biopha.2025.117893_bib46","doi-asserted-by":"crossref","first-page":"2135","DOI":"10.1016\/0006-2952(94)90515-0","article-title":"Purine substrates for human thiopurine methyltransferase","volume":"48","author":"Deininger","year":"1994","journal-title":"Biochem. Pharmacol."},{"key":"10.1016\/j.biopha.2025.117893_bib47","doi-asserted-by":"crossref","first-page":"900","DOI":"10.1039\/b919371p","article-title":"Enzymes that catalyse SN2 reaction mechanisms","volume":"27","author":"O\u2019Hagan","year":"2010","journal-title":"Nat. Prod. Rep."},{"key":"10.1016\/j.biopha.2025.117893_bib48","doi-asserted-by":"crossref","first-page":"1078","DOI":"10.1016\/S0021-9258(18)81262-5","article-title":"Metabolism of thiopyrimidines and thiopurines. S-Methylation with S-adenosylmethionine transmethylase and catabolism in mammalian tissues","volume":"238","author":"Remy","year":"1963","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.biopha.2025.117893_bib49","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1016\/S0022-3565(25)38338-2","article-title":"Diethyldithiocarbamate S-methylation: evidence for catalysis by human liver thiol methyltransferase and thiopurine methyltransferase","volume":"266","author":"Glauser","year":"1993","journal-title":"J. Pharmacol. Exp. Ther."},{"key":"10.1016\/j.biopha.2025.117893_bib50","doi-asserted-by":"crossref","first-page":"2467","DOI":"10.1021\/acs.chemrestox.0c00254","article-title":"Production of a Urinary Selenium Metabolite, Trimethylselenonium, by Thiopurine S-Methyltransferase and Indolethylamine N-Methyltransferase","volume":"33","author":"Fukumoto","year":"2020","journal-title":"Chem. Res. Toxicol."},{"key":"10.1016\/j.biopha.2025.117893_bib51","doi-asserted-by":"crossref","first-page":"354","DOI":"10.1021\/jm00153a009","article-title":"Thiopurine methyltransferase: structure-activity relationships for benzoic acid inhibitors and thiophenol substrates","volume":"29","author":"Ames","year":"1986","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.biopha.2025.117893_bib52","doi-asserted-by":"crossref","first-page":"4965","DOI":"10.1158\/0008-5472.CAN-06-3508","article-title":"Differential effects of targeted disruption of thiopurine methyltransferase on mercaptopurine and thioguanine pharmacodynamics","volume":"67","author":"Hartford","year":"2007","journal-title":"Cancer Res"},{"key":"10.1016\/j.biopha.2025.117893_bib53","doi-asserted-by":"crossref","first-page":"1141","DOI":"10.1016\/S0026-895X(25)08754-1","article-title":"Methylation of mercaptopurine, thioguanine, and their nucleotide metabolites by heterologously expressed human thiopurine S-methyltransferase","volume":"47","author":"Krynetski","year":"1995","journal-title":"Mol. Pharmacol."},{"key":"10.1016\/j.biopha.2025.117893_bib54","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1007\/s002280050630","article-title":"Inhibition of thiopurine S-methyltransferase activity by impurities in commercially available substrates: a factor for differing results of TPMT measurements","volume":"55","author":"Kr\u00f6plin","year":"1999","journal-title":"Eur. J. Clin. Pharmacol."},{"key":"10.1016\/j.biopha.2025.117893_bib55","doi-asserted-by":"crossref","first-page":"174","DOI":"10.1016\/S0022-3565(25)33170-8","article-title":"Pharmacogenetics of human thiopurine methyltransferase: kidney-erythrocyte correlation and immunotitration studies","volume":"222","author":"Woodson","year":"1982","journal-title":"J. Pharmacol. Exp. Ther."},{"key":"10.1016\/j.biopha.2025.117893_bib56","doi-asserted-by":"crossref","first-page":"610","DOI":"10.1093\/ecco-jcc\/jjx181","article-title":"Thiopurines in inflammatory bowel disease: new findings and perspectives","volume":"12","author":"de Boer","year":"2018","journal-title":"J. Crohns Colitis"},{"key":"10.1016\/j.biopha.2025.117893_bib57","doi-asserted-by":"crossref","first-page":"1286","DOI":"10.1111\/apt.15743","article-title":"Review article: opportunities to improve and expand thiopurine therapy for autoimmune hepatitis","volume":"51","author":"Czaja","year":"2020","journal-title":"Aliment. Pharmacol. Ther."},{"key":"10.1016\/j.biopha.2025.117893_bib58","first-page":"256","article-title":"G. Decorti, Pharmacogenetics of thiopurines","volume":"2","author":"Franca","year":"2019","journal-title":"Cancer Drug Resist."},{"key":"10.1016\/j.biopha.2025.117893_bib59","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1007\/BF02220605","article-title":"The clinical pharmacology of 6-mercaptopurine","volume":"43","author":"Lennard","year":"1992","journal-title":"Eur. J. Clin. Pharmacol."},{"key":"10.1016\/j.biopha.2025.117893_bib60","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1111\/j.1365-2036.2011.04905.x","article-title":"Review article: the benefits of pharmacogenetics for improving thiopurine therapy in inflammatory bowel disease","volume":"35","author":"Chouchana","year":"2012","journal-title":"Aliment. Pharmacol. Ther."},{"key":"10.1016\/j.biopha.2025.117893_bib61","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1038\/clpt.1989.119","article-title":"Pharmacogenetics of acute azathioprine toxicity: relationship to thiopurine methyltransferase genetic polymorphism","volume":"46","author":"Lennard","year":"1989","journal-title":"Clin. Pharmacol. Ther."},{"key":"10.1016\/j.biopha.2025.117893_bib62","doi-asserted-by":"crossref","first-page":"3533","DOI":"10.1016\/0006-2952(86)90623-4","article-title":"Concurrent unilateral chromatid damage and DNA strand breakage in response to 6-thioguanine treatment","volume":"35","author":"Fairchild","year":"1986","journal-title":"Biochem. Pharmacol."},{"key":"10.1016\/j.biopha.2025.117893_bib63","doi-asserted-by":"crossref","first-page":"1109","DOI":"10.1126\/science.273.5278.1109","article-title":"Role of postreplicative DNA mismatch repair in the cytotoxic action of thioguanine","volume":"273","author":"Swann","year":"1996","journal-title":"Science"},{"key":"10.1016\/j.biopha.2025.117893_bib64","first-page":"417","article-title":"Delayed cytotoxicity of 6-mercaptopurine is compatible with mitotic death caused by DNA damage due to incorporation of 6-thioguanine into DNA as 6-thioguanine nucleotide","volume":"18","author":"Inamochi","year":"1999","journal-title":"J. Exp. Clin. Cancer Res."},{"key":"10.1016\/j.biopha.2025.117893_bib65","doi-asserted-by":"crossref","first-page":"841","DOI":"10.1016\/S0026-895X(24)12548-5","article-title":"Human RNase H-Mediated RNA Cleavage from DNA-RNA duplexes is inhibited by 6-deoxythioguanosine incorporation into DNA","volume":"56","author":"Krynetskaia","year":"1999","journal-title":"Mol. Pharm."},{"key":"10.1016\/j.biopha.2025.117893_bib66","doi-asserted-by":"crossref","first-page":"1133","DOI":"10.1172\/JCI16432","article-title":"CD28-dependent Rac1 activation is the molecular target of azathioprine in primary human CD4+\u2009T lymphocytes","volume":"111","author":"Tiede","year":"2003","journal-title":"J. Clin. Invest."},{"key":"10.1016\/j.biopha.2025.117893_bib67","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1016\/0925-4439(93)90110-M","article-title":"The importance of methylthio-IMP for methylmercaptopurine ribonucleoside (Me-MPR) cytotoxicity in Molt F4 human malignant T-lymphoblasts","volume":"1181","author":"Vogt","year":"1993","journal-title":"Biochim. Biophys. Acta"},{"key":"10.1016\/j.biopha.2025.117893_bib68","doi-asserted-by":"crossref","first-page":"542","DOI":"10.2174\/1389200217666160303104153","article-title":"Thiopurine biotransformation and pharmacological effects: contribution of oxidative stress","volume":"17","author":"Pelin","year":"2016","journal-title":"Curr. Drug Metab."},{"key":"10.1016\/j.biopha.2025.117893_bib69","first-page":"257","article-title":"Mechanisms of action of drugs affecting immune responses: significance of azathioprine metabolites","volume":"65","author":"Elion","year":"1972","journal-title":"Proc. R. Soc. Med."},{"key":"10.1016\/j.biopha.2025.117893_bib70","doi-asserted-by":"crossref","DOI":"10.1002\/cpt.1304","article-title":"Clinical pharmacogenetics implementation consortium guideline for thiopurine dosing based on TPMT and NUDT15 Genotypes: 2018 Update","author":"Relling","year":"2019","journal-title":"Clin. Pharmacol. Ther."},{"key":"10.1016\/j.biopha.2025.117893_bib71","doi-asserted-by":"crossref","first-page":"567","DOI":"10.1038\/sj.leu.2401723","article-title":"Genetic polymorphism of thiopurine methyltransferase and its clinical relevance for childhood acute lymphoblastic leukemia","volume":"14","author":"McLeod","year":"2000","journal-title":"Leukemia"},{"key":"10.1016\/j.biopha.2025.117893_bib72","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1002\/cpt.463","article-title":"Genomewide approach validates thiopurine methyltransferase activity is a monogenic pharmacogenomic trait","volume":"101","author":"Liu","year":"2017","journal-title":"Clin. Pharmacol. Ther."},{"key":"10.1016\/j.biopha.2025.117893_bib73","doi-asserted-by":"crossref","first-page":"146","DOI":"10.1002\/pbc.26189","article-title":"NUDT15 and TPMT genetic polymorphisms are related to 6-mercaptopurine intolerance in children treated for acute lymphoblastic leukemia at the Children\u2019s Cancer Center of Lebanon","volume":"64","author":"Zgheib","year":"2017","journal-title":"Pedia Blood Cancer"},{"key":"10.1016\/j.biopha.2025.117893_bib74","doi-asserted-by":"crossref","first-page":"1289","DOI":"10.3349\/ymj.2014.55.5.1289","article-title":"Monitoring thiopurine metabolites in korean pediatric patients with inflammatory bowel disease","volume":"55","author":"Kim","year":"2014","journal-title":"Yonsei Med. J."},{"key":"10.1016\/j.biopha.2025.117893_bib75","doi-asserted-by":"crossref","first-page":"2293","DOI":"10.1200\/JCO.2001.19.8.2293","article-title":"Preponderance of thiopurine S-methyltransferase deficiency and heterozygosity among patients intolerant to mercaptopurine or azathioprine","volume":"19","author":"Evans","year":"2001","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.biopha.2025.117893_bib76","doi-asserted-by":"crossref","first-page":"550","DOI":"10.1111\/bjh.13469","article-title":"Thiopurine methyltransferase and treatment outcome in the UK acute lymphoblastic leukaemia trial ALL2003","volume":"170","author":"Lennard","year":"2015","journal-title":"Br. J. Haematol."},{"key":"10.1016\/j.biopha.2025.117893_bib77","unstructured":"TPMT - Clinical Guideline Annotations, PharmGKB (n.d.). \u3008https:\/\/www.pharmgkb.org\/gene\/PA356\/guidelineAnnotation\u3009 (accessed December 14, 2020)."},{"key":"10.1016\/j.biopha.2025.117893_bib78","first-page":"294","article-title":"The Activity of 6-Selenopurine and Related Compounds against Some Experimental Mouse Tumors","volume":"18","author":"Mautner","year":"1958","journal-title":"Cancer Res"},{"key":"10.1016\/j.biopha.2025.117893_bib79","first-page":"381","article-title":"A comparison of the biological properties of 6-selenopurine, 6-selenopurine ribonucleoside, and 6-mercaptopurine in mice","volume":"20","author":"Jaffe","year":"1960","journal-title":"Cancer Res"},{"key":"10.1016\/j.biopha.2025.117893_bib80","doi-asserted-by":"crossref","first-page":"1343","DOI":"10.1002\/jps.2600640818","article-title":"Synthesis and cytotoxicity of 6-selenopurine arabinoside and related compounds","volume":"64","author":"Chu","year":"1975","journal-title":"J. Pharm. Sci."},{"key":"10.1016\/j.biopha.2025.117893_bib81","doi-asserted-by":"crossref","first-page":"8870","DOI":"10.1039\/c3cs60272a","article-title":"Which form is that? The importance of selenium speciation and metabolism in the prevention and treatment of disease","volume":"42","author":"Weekley","year":"2013","journal-title":"Chem. Soc. Rev."},{"key":"10.1016\/j.biopha.2025.117893_bib82","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1039\/C3MT00185G","article-title":"Selenium biochemistry and its role for human health","volume":"6","author":"Roman","year":"2014","journal-title":"Metallomics"},{"key":"10.1016\/j.biopha.2025.117893_bib83","doi-asserted-by":"crossref","first-page":"110","DOI":"10.1111\/j.1365-313X.2009.03855.x","article-title":"Characterization of selenocysteine methyltransferases from Astragalus species with contrasting selenium accumulation capacity","volume":"59","author":"Sors","year":"2009","journal-title":"Plant J."},{"key":"10.1016\/j.biopha.2025.117893_bib84","doi-asserted-by":"crossref","first-page":"377","DOI":"10.1104\/pp.103.026989","article-title":"Overexpression of selenocysteine methyltransferase in arabidopsis and Indian Mustard increases selenium tolerance and accumulation","volume":"135","author":"LeDuc","year":"2004","journal-title":"Plant Physiol."},{"key":"10.1016\/j.biopha.2025.117893_bib85","doi-asserted-by":"crossref","first-page":"821","DOI":"10.1021\/acschembio.6b00031","article-title":"Why nature chose selenium","volume":"11","author":"Reich","year":"2016","journal-title":"ACS Chem. Biol."},{"key":"10.1016\/j.biopha.2025.117893_bib86","doi-asserted-by":"crossref","first-page":"3232","DOI":"10.3390\/molecules16043232","article-title":"Selenol protecting groups in organic chemistry: special emphasis on selenocysteine Se-protection in solid phase peptide synthesis","volume":"16","author":"Flemer","year":"2011","journal-title":"Molecules"},{"key":"10.1016\/j.biopha.2025.117893_bib87","doi-asserted-by":"crossref","first-page":"3146","DOI":"10.1128\/JB.184.11.3146-3149.2002","article-title":"Methylation of inorganic and organic selenium by the bacterial thiopurine methyltransferase","volume":"184","author":"Ranjard","year":"2002","journal-title":"J. Bacteriol."},{"key":"10.1016\/j.biopha.2025.117893_bib88","doi-asserted-by":"crossref","first-page":"3784","DOI":"10.1128\/AEM.69.7.3784-3790.2003","article-title":"Freshwater bacteria can methylate selenium through the thiopurine methyltransferase pathway","volume":"69","author":"Ranjard","year":"2003","journal-title":"Appl. Environ. Microbiol."},{"key":"10.1016\/j.biopha.2025.117893_bib89","doi-asserted-by":"crossref","first-page":"1573","DOI":"10.1016\/j.biochi.2006.09.005","article-title":"Distribution and genetic diversity of bacterial thiopurine methyltransferases in soils emitting dimethyl selenide","volume":"88","author":"Favre-Bont\u00e9","year":"2006","journal-title":"Biochimie"},{"key":"10.1016\/j.biopha.2025.117893_bib90","doi-asserted-by":"crossref","DOI":"10.1016\/j.jbc.2023.105599","article-title":"Differential molecular mechanisms of substrate recognition by selenium methyltransferases, INMT and TPMT, in selenium detoxification and excretion","volume":"300","author":"Fukumoto","year":"2024","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.biopha.2025.117893_bib91","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1016\/S0167-4781(98)00020-7","article-title":"A tellurite-resistance genetic determinant from phytopathogenic pseudomonads encodes a thiopurine methyltransferase: evidence of a widely-conserved family of methyltransferases","volume":"1397","author":"Cournoyer","year":"1998","journal-title":"Biochim. Biophys. Acta"},{"key":"10.1016\/j.biopha.2025.117893_bib92","doi-asserted-by":"crossref","first-page":"6509","DOI":"10.1128\/JB.182.22.6509-6513.2000","article-title":"Escherichia coli TehB requires S-adenosylmethionine as a cofactor to mediate tellurite resistance","volume":"182","author":"Liu","year":"2000","journal-title":"J. Bacteriol."},{"key":"10.1016\/j.biopha.2025.117893_bib93","doi-asserted-by":"crossref","first-page":"94","DOI":"10.1089\/ars.2012.4521","article-title":"Understanding the pKa of Redox Cysteines: The Key Role of Hydrogen Bonding","volume":"18","author":"Roos","year":"2012","journal-title":"Antioxid. Redox Signal."},{"key":"10.1016\/j.biopha.2025.117893_bib94","doi-asserted-by":"crossref","first-page":"393","DOI":"10.1007\/BF00203784","article-title":"Inhibition of human thiopurine methyltransferase by furosemide, bendroflumethiazide and trichlormethiazide","volume":"49","author":"Lysaa","year":"1996","journal-title":"Eur. J. Clin. Pharmacol."},{"key":"10.1016\/j.biopha.2025.117893_bib95","doi-asserted-by":"crossref","first-page":"456","DOI":"10.1111\/j.1365-2125.1995.tb04478.x","article-title":"Sulphasalazine inhibition of thiopurine methyltransferase: possible mechanism for interaction with 6-mercaptopurine and azathioprine","volume":"39","author":"Szumlanski","year":"1995","journal-title":"Br. J. Clin. Pharm."},{"key":"10.1016\/j.biopha.2025.117893_bib96","doi-asserted-by":"crossref","first-page":"464","DOI":"10.1016\/S0009-9236(97)90125-9","article-title":"Olsalazine and 6-mercaptopurine-related bone marrow suppression: A possible drug-drug interaction","volume":"62","author":"Lewis","year":"1997","journal-title":"Clin. Pharmacol. Ther."},{"key":"10.1016\/j.biopha.2025.117893_bib97","doi-asserted-by":"crossref","first-page":"1105","DOI":"10.1111\/j.1365-2036.2005.02460.x","article-title":"Effects of aminosalicylates on thiopurine S-methyltransferase activity: an ex vivo study in patients with inflammatory bowel disease","volume":"21","author":"Xin","year":"2005","journal-title":"Aliment. Pharmacol. Ther."},{"key":"10.1016\/j.biopha.2025.117893_bib98","doi-asserted-by":"crossref","first-page":"1452","DOI":"10.1124\/dmd.107.016287","article-title":"Inhibition of human thiopurine S-methyltransferase by various nonsteroidal anti-inflammatory drugs in vitro: a mechanism for possible drug interactions","volume":"35","author":"Oselin","year":"2007","journal-title":"Drug Metab. Dispos."},{"key":"10.1016\/j.biopha.2025.117893_bib99","doi-asserted-by":"crossref","first-page":"539","DOI":"10.1016\/j.bcp.2013.06.002","article-title":"Mechanism of allopurinol induced TPMT inhibition","volume":"86","author":"Blaker","year":"2013","journal-title":"Biochem. Pharmacol."},{"key":"10.1016\/j.biopha.2025.117893_bib100","doi-asserted-by":"crossref","first-page":"656","DOI":"10.1136\/gut.49.5.656","article-title":"Leucopenia resulting from a drug interaction between azathioprine or 6-mercaptopurine and mesalamine, sulphasalazine, or balsalazide","volume":"49","author":"Lowry","year":"2001","journal-title":"Gut"},{"key":"10.1016\/j.biopha.2025.117893_bib101","doi-asserted-by":"crossref","first-page":"1641","DOI":"10.1007\/s00228-013-1521-9","article-title":"Methotrexate binds to recombinant thiopurine S-methyltransferase and inhibits enzyme activity after high-dose infusions in childhood leukaemia","volume":"69","author":"Wennerstrand","year":"2013","journal-title":"Eur. J. Clin. Pharmacol."},{"key":"10.1016\/j.biopha.2025.117893_bib102","doi-asserted-by":"crossref","first-page":"395","DOI":"10.1007\/s00228-005-0950-5","article-title":"Thiopurine S-methyltransferase as a target for drug interactions","volume":"61","author":"Xin","year":"2005","journal-title":"Eur. J. Clin. Pharm."},{"key":"10.1016\/j.biopha.2025.117893_bib103","doi-asserted-by":"crossref","first-page":"784","DOI":"10.1021\/ja01585a023","article-title":"Potential Purine Antagonists. I. Synthesis of Some 4,6-Substituted Pyrazolo [3,4-d] pyrimidines1","volume":"78","author":"Robins","year":"1956","journal-title":"J. Am. Chem. Soc."},{"key":"10.1016\/j.biopha.2025.117893_bib104","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1016\/0006-2952(63)90012-1","article-title":"Potentiation by inhibition of drug degradation: 6-substituted purines and xanthine oxidase","volume":"12","author":"Elion","year":"1963","journal-title":"Biochem. Pharmacol."},{"key":"10.1016\/j.biopha.2025.117893_bib105","doi-asserted-by":"crossref","first-page":"548","DOI":"10.1016\/0002-9343(66)90118-5","article-title":"Metabolic and therapeutic effects of allopurinol in patients with leukemia and gout","volume":"40","author":"Vogler","year":"1966","journal-title":"Am. J. Med."},{"key":"10.1016\/j.biopha.2025.117893_bib106","doi-asserted-by":"crossref","first-page":"717","DOI":"10.7326\/0003-4819-60-4-717_2","article-title":"Effects of xanthine oxidase inhibitor on clinical manifestations and purine metabolism in gout","volume":"60","author":"Rundles","year":"1964","journal-title":"Ann. Intern. Med."},{"key":"10.1016\/j.biopha.2025.117893_bib107","doi-asserted-by":"crossref","first-page":"655","DOI":"10.1136\/annrheumd00512-0057","article-title":"Effects of Allopurinol on 6-mercaptopurine therapy in neoplastic diseases","volume":"25","author":"Rundles","year":"1966","journal-title":"Ann. Rheum. Dis."},{"key":"10.1016\/j.biopha.2025.117893_bib108","doi-asserted-by":"crossref","first-page":"623","DOI":"10.2165\/00003088-200746080-00001","article-title":"Clinical pharmacokinetics and pharmacodynamics of allopurinol and oxypurinol","volume":"46","author":"Day","year":"2007","journal-title":"Clin. Pharm."},{"key":"10.1016\/j.biopha.2025.117893_bib109","doi-asserted-by":"crossref","first-page":"1114","DOI":"10.1002\/pbc.24913","article-title":"Use of allopurinol in children with acute lymphoblastic leukemia to reduce skewed thiopurine metabolism","volume":"61","author":"Brackett","year":"2014","journal-title":"Pedia Blood Cancer"},{"key":"10.1016\/j.biopha.2025.117893_bib110","doi-asserted-by":"crossref","first-page":"441","DOI":"10.1111\/j.1365-2036.2005.02583.x","article-title":"Allopurinol safely and effectively optimizes tioguanine metabolites in inflammatory bowel disease patients not responding to azathioprine and mercaptopurine","volume":"22","author":"Sparrow","year":"2005","journal-title":"Aliment. Pharmacol. Ther."},{"key":"10.1016\/j.biopha.2025.117893_bib111","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1016\/0140-6736(93)91287-V","article-title":"Low-dose allopurinol plus azathioprine\/cyclosporin\/prednisolone, a novel immunosuppressive regimen","volume":"342","author":"Chocair","year":"1993","journal-title":"Lancet"},{"key":"10.1016\/j.biopha.2025.117893_bib112","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1016\/j.cgh.2006.11.020","article-title":"Effect of allopurinol on clinical outcomes in inflammatory bowel disease nonresponders to azathioprine or 6-mercaptopurine","volume":"5","author":"Sparrow","year":"2007","journal-title":"Clin. Gastroenterol. Hepatol."},{"key":"10.1016\/j.biopha.2025.117893_bib113","doi-asserted-by":"crossref","DOI":"10.1016\/j.dld.2018.02.001","article-title":"Low-dose thiopurine with allopurinol co-therapy overcomes thiopurine intolerance and allows thiopurine continuation in inflammatory bowel disease","author":"Vasudevan","year":"2018","journal-title":"Dig. Liver Dis."},{"key":"10.1016\/j.biopha.2025.117893_bib114","doi-asserted-by":"crossref","first-page":"734","DOI":"10.1111\/j.1365-2036.2008.03782.x","article-title":"Long-term outcome of using allopurinol co-therapy as a strategy for overcoming thiopurine hepatotoxicity in treating inflammatory bowel disease","volume":"28","author":"Ansari","year":"2008","journal-title":"Aliment. Pharmacol. Ther."},{"key":"10.1016\/j.biopha.2025.117893_bib115","doi-asserted-by":"crossref","first-page":"1639","DOI":"10.1097\/MIB.0000000000000827","article-title":"Long-term safety and efficacy of low-dose azathioprine and allopurinol cotherapy in inflammatory bowel disease: a large observational study","volume":"22","author":"Pavlidis","year":"2016","journal-title":"Inflamm. Bowel Dis."},{"key":"10.1016\/j.biopha.2025.117893_bib116","doi-asserted-by":"crossref","first-page":"905","DOI":"10.1016\/j.crohns.2012.02.007","article-title":"Optimising outcome on thiopurines in inflammatory bowel disease by co-prescription of allopurinol","volume":"6","author":"Smith","year":"2012","journal-title":"J. Crohns Colitis"},{"key":"10.1016\/j.biopha.2025.117893_bib117","doi-asserted-by":"crossref","unstructured":"J.P.A. Houwen, A.C.G. Egberts, A. de Boer, E.M. van Maarseveen, R.H.J. Houwen, A. Lalmohamed, Influence of allopurinol on thiopurine associated toxicity: A retrospective population-based cohort study, British Journal of Clinical Pharmacology n\/a (n.d.). https:\/\/doi.org\/10.1111\/bcp.14625.","DOI":"10.1111\/bcp.14625"},{"key":"10.1016\/j.biopha.2025.117893_bib118","doi-asserted-by":"crossref","DOI":"10.3324\/haematol.2023.284390","article-title":"Effects of allopurinol on 6-mercaptopurine metabolism in unselected patients with pediatric acute lymphoblastic leukemia: a prospective phase II study","author":"K\u00e4llstr\u00f6m","year":"2024","journal-title":"Haematologica"},{"key":"10.1016\/j.biopha.2025.117893_bib119","doi-asserted-by":"crossref","first-page":"504","DOI":"10.1111\/apt.17831","article-title":"Clinical trial: Combination allopurinol-thiopurine versus standard thiopurine in patients with IBD escalating to immunomodulators (the DECIDER study)","volume":"59","author":"Vasudevan","year":"2024","journal-title":"Aliment Pharm. Ther."},{"key":"10.1016\/j.biopha.2025.117893_bib120","doi-asserted-by":"crossref","first-page":"250","DOI":"10.1007\/s10620-011-1999-x","article-title":"Two brothers with skewed thiopurine metabolism in ulcerative colitis treated successfully with allopurinol and mercaptopurine dose reduction","volume":"57","author":"Hoentjen","year":"2012","journal-title":"Dig. Dis. Sci."},{"key":"10.1016\/j.biopha.2025.117893_bib121","doi-asserted-by":"crossref","first-page":"819","DOI":"10.1177\/1756283X17733657","article-title":"Allopurinol in combination with thiopurine induces mucosal healing and improves clinical and metabolic outcomes in IBD","volume":"10","author":"Moreau","year":"2017","journal-title":"Ther. Adv. Gastroenterol."},{"key":"10.1016\/j.biopha.2025.117893_bib122","doi-asserted-by":"crossref","first-page":"407","DOI":"10.1111\/apt.15402","article-title":"Real-life study of safety of thiopurine-allopurinol combination therapy in inflammatory bowel disease: myelotoxicity and hepatotoxicity rarely affect maintenance treatment","volume":"50","author":"Kreijne","year":"2019","journal-title":"Aliment. Pharmacol. Ther."},{"key":"10.1016\/j.biopha.2025.117893_bib123","doi-asserted-by":"crossref","first-page":"1669","DOI":"10.1007\/s00228-019-02760-8","article-title":"Thiopurines with low-dose allopurinol (ThiLDA)\u2014a prospective clinical one-way crossover trial","volume":"75","author":"Chavoushi","year":"2019","journal-title":"Eur. J. Clin. Pharm."},{"key":"10.1016\/j.biopha.2025.117893_bib124","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1136\/flgastro-2014-100504","article-title":"Low dose thiopurine and allopurinol co-therapy results in significant cost savings at a district general hospital","volume":"6","author":"Dharmasiri","year":"2015","journal-title":"Frontline Gastroenterol."},{"key":"10.1016\/j.biopha.2025.117893_bib125","doi-asserted-by":"crossref","first-page":"712","DOI":"10.1002\/pbc.25841","article-title":"Maintenance Treatment With Low-Dose Mercaptopurine in Combination With Allopurinol in Children With Acute Lymphoblastic Leukemia and Mercaptopurine-Induced Pancreatitis","volume":"63","author":"Zerra","year":"2016","journal-title":"Pedia Blood Cancer"},{"key":"10.1016\/j.biopha.2025.117893_bib126","doi-asserted-by":"crossref","first-page":"1281","DOI":"10.1002\/hep.26198","article-title":"Use of a xanthine oxidase inhibitor in autoimmune hepatitis","volume":"57","author":"Al-Shamma","year":"2013","journal-title":"Hepatology"},{"key":"10.1016\/j.biopha.2025.117893_bib127","doi-asserted-by":"crossref","first-page":"524","DOI":"10.1097\/MPG.0b013e3181d29750","article-title":"Allopurinol salvage therapy in pediatric overlap autoimmune hepatitis-primary sclerosing cholangitis with 6-MMP toxicity","volume":"51","author":"Dunkin","year":"2010","journal-title":"J. Pediatr. Gastroenterol. Nutr."},{"key":"10.1016\/j.biopha.2025.117893_bib128","doi-asserted-by":"crossref","first-page":"35","DOI":"10.4322\/acr.2017.021","article-title":"Histological remission of autoimmune hepatitis after the addition of allopurinol and azathioprine dose reduction","volume":"7","author":"Guedes","year":"2017","journal-title":"Autops Case Rep."},{"key":"10.1016\/j.biopha.2025.117893_bib129","doi-asserted-by":"crossref","first-page":"695","DOI":"10.1097\/MPG.0000000000002146","article-title":"Lower 6-MMP\/6-TG Ratio May Be a Therapeutic Target in Pediatric Autoimmune Hepatitis","volume":"67","author":"Bolia","year":"2018","journal-title":"J. Pedia Gastroenterol. Nutr."},{"key":"10.1016\/j.biopha.2025.117893_bib130","doi-asserted-by":"crossref","DOI":"10.1093\/ehjcr\/ytaa326","article-title":"Pancytopenia caused by allopurinol and azathioprine interaction in a heart transplant patient: a case report","author":"Feinman","year":"2020","journal-title":"Eur. Heart J. - Case Rep."},{"key":"10.1016\/j.biopha.2025.117893_bib131","doi-asserted-by":"crossref","DOI":"10.1002\/ccr3.4696","article-title":"Azathioprine-induced severe myelosuppression accompanied by massive hair loss and painful oral ulcer in an autoimmune hepatitis patient with NUDT15 minor variant: A case report","volume":"9","author":"Takeuchi","year":"2021","journal-title":"Clin. Case Rep."},{"key":"10.1016\/j.biopha.2025.117893_bib132","doi-asserted-by":"crossref","first-page":"1083","DOI":"10.1111\/j.1476-5381.2010.00731.x","article-title":"Influence of 5-aminosalicylic acid on 6-thioguanosine phosphate metabolite levels: a prospective study in patients under steady thiopurine therapy","volume":"160","author":"de Graaf","year":"2010","journal-title":"Br. J. Pharmacol."},{"key":"10.1016\/j.biopha.2025.117893_bib133","doi-asserted-by":"crossref","first-page":"958","DOI":"10.1097\/MEG.0b013e3283545ae3","article-title":"The potential influence of 5-aminosalicylic acid on the induction of myelotoxicity during thiopurine therapy in inflammatory bowel disease patients","volume":"24","author":"Gao","year":"2012","journal-title":"Eur. J. Gastroenterol. Hepatol."},{"key":"10.1016\/j.biopha.2025.117893_bib134","doi-asserted-by":"crossref","first-page":"605","DOI":"10.1111\/j.1365-2036.2005.02630.x","article-title":"The pharmacokinetic effect of discontinuation of mesalazine on mercaptopurine metabolite levels in inflammatory bowel disease patients","volume":"22","author":"Gilissen","year":"2005","journal-title":"Aliment. Pharmacol. Ther."},{"key":"10.1016\/j.biopha.2025.117893_bib135","doi-asserted-by":"crossref","first-page":"640","DOI":"10.1111\/apt.12223","article-title":"Allopurinol safely and effectively optimises thiopurine metabolites in patients with autoimmune hepatitis","volume":"37","author":"de Boer","year":"2013","journal-title":"Aliment Pharm. Ther."},{"key":"10.1016\/j.biopha.2025.117893_bib136","doi-asserted-by":"crossref","first-page":"3571","DOI":"10.3748\/wjg.v21.i12.3571","article-title":"Thiopurine metabolites variations during co-treatment with aminosalicylates for inflammatory bowel disease: effect of N-acetyl transferase polymorphisms","volume":"21","author":"Stocco","year":"2015","journal-title":"World J. Gastroenterol."},{"key":"10.1016\/j.biopha.2025.117893_bib137","doi-asserted-by":"crossref","first-page":"2747","DOI":"10.1111\/j.1572-0241.2007.01511.x","article-title":"Dose-dependent influence of 5-aminosalicylates on thiopurine metabolism","volume":"102","author":"de Boer","year":"2007","journal-title":"Am. J. Gastroenterol."},{"key":"10.1016\/j.biopha.2025.117893_bib138","doi-asserted-by":"crossref","first-page":"3246","DOI":"10.1007\/s10620-008-0283-1","article-title":"Interruption of mesalamine and reduction of the blood concentration of the active metabolites of azathioprine: possible causes of ulcerative colitis relapse","volume":"53","author":"Stocco","year":"2008","journal-title":"Dig. Dis. Sci."},{"key":"10.1016\/j.biopha.2025.117893_bib139","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1046\/j.1365-2036.2002.01156.x","article-title":"Interaction between azathioprine and aminosalicylates: an in vivo study in patients with Crohn\u2019s disease","volume":"16","author":"Dewit","year":"2002","journal-title":"Aliment. Pharmacol. Ther."},{"key":"10.1016\/j.biopha.2025.117893_bib140","doi-asserted-by":"crossref","first-page":"238","DOI":"10.1159\/000495690","article-title":"pH-dependent 5-aminosalicylates releasing preparations do not affect thiopurine metabolism","volume":"100","author":"Takahashi","year":"2019","journal-title":"Digestion"},{"key":"10.1016\/j.biopha.2025.117893_bib141","doi-asserted-by":"crossref","first-page":"2116","DOI":"10.1111\/jgh.15411","article-title":"Differential effects of mesalazine formulations on thiopurine metabolism through thiopurine S-methyltransferase inhibition","volume":"36","author":"Morikubo","year":"2021","journal-title":"J. Gastroenterol. Hepatol."},{"key":"10.1016\/j.biopha.2025.117893_bib142","doi-asserted-by":"crossref","first-page":"539","DOI":"10.1093\/ibd\/izx065","article-title":"Combination Immunosuppression in IBD","volume":"24","author":"Bots","year":"2018","journal-title":"Inflamm. Bowel Dis."},{"key":"10.1016\/j.biopha.2025.117893_bib143","first-page":"328","article-title":"Management strategies in acute lymphoblastic leukemia","volume":"25","author":"Rabin","year":"2011","journal-title":"Oncol. (Williston Park, N. Y. )"},{"key":"10.1016\/j.biopha.2025.117893_bib144","doi-asserted-by":"crossref","first-page":"1165","DOI":"10.1182\/blood-2012-05-378943","article-title":"Pediatric acute lymphoblastic leukemia: where are we going and how do we get there?","volume":"120","author":"Pui","year":"2012","journal-title":"Blood"},{"key":"10.1016\/j.biopha.2025.117893_bib145","doi-asserted-by":"crossref","first-page":"320","DOI":"10.1038\/leu.2009.253","article-title":"Long-term results of Dana-Farber Cancer Institute ALL Consortium protocols for children with newly diagnosed acute lymphoblastic leukemia (1985-2000)","volume":"24","author":"Silverman","year":"2010","journal-title":"Leukemia"},{"key":"10.1016\/j.biopha.2025.117893_bib146","article-title":"Pharmacogenetic studies of thiopurine methyltransferase genotype-phenotype concordance and effect of methotrexate on thiopurine metabolism","author":"Zimdahl Kahlin","year":"2020","journal-title":"Basic Clin. Pharm. Toxicol."},{"key":"10.1016\/j.biopha.2025.117893_bib147","doi-asserted-by":"crossref","first-page":"503","DOI":"10.1097\/MPH.0000000000000206","article-title":"Mercaptopurine\/Methotrexate maintenance therapy of childhood acute lymphoblastic leukemia: clinical facts and fiction","volume":"36","author":"Schmiegelow","year":"2014","journal-title":"J. Pediatr. Hematol. Oncol."},{"key":"10.1016\/j.biopha.2025.117893_bib148","doi-asserted-by":"crossref","first-page":"1749","DOI":"10.1038\/s41375-022-01591-4","article-title":"Maintenance therapy for acute lymphoblastic leukemia: basic science and clinical translations","volume":"36","author":"Toksvang","year":"2022","journal-title":"Leukemia"},{"key":"10.1016\/j.biopha.2025.117893_bib149","doi-asserted-by":"crossref","first-page":"1783","DOI":"10.1016\/S0140-6736(96)91615-3","article-title":"Duration and intensity of maintenance chemotherapy in acute lymphoblastic leukaemia: overview of 42 trials involving 12 000 randomised children","volume":"347","author":"Childhood ALL Collaborative Group","year":"1996","journal-title":"Lancet"},{"key":"10.1016\/j.biopha.2025.117893_bib150","doi-asserted-by":"crossref","first-page":"983","DOI":"10.1007\/s00280-016-3151-2","article-title":"Measures of 6-mercaptopurine and methotrexate maintenance therapy intensity in childhood acute lymphoblastic leukemia","volume":"78","author":"Nielsen","year":"2016","journal-title":"Cancer Chemother. Pharmacol."},{"key":"10.1016\/j.biopha.2025.117893_bib151","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1038\/sj.leu.2402373","article-title":"Effect of methotrexate polyglutamates on thioguanine nucleotide concentrations during continuation therapy of acute lymphoblastic leukemia with mercaptopurine","volume":"16","author":"Dervieux","year":"2002","journal-title":"Leukemia"},{"key":"10.1016\/j.biopha.2025.117893_bib152","doi-asserted-by":"crossref","first-page":"384","DOI":"10.1038\/clpt.1987.45","article-title":"The effect of methotrexate on the bioavailability of oral 6-mercaptopurine","volume":"41","author":"Balis","year":"1987","journal-title":"Clin. Pharmacol. Ther."},{"key":"10.1016\/j.biopha.2025.117893_bib153","doi-asserted-by":"crossref","first-page":"506","DOI":"10.1016\/S0009-9236(03)00063-8","article-title":"M.V. Relling, Antagonism by methotrexate on mercaptopurine disposition in lymphoblasts during up-front treatment of acute lymphoblastic leukemia","volume":"73","author":"Dervieux","year":"2003","journal-title":"Clin. Pharmacol. Ther."},{"key":"10.1016\/j.biopha.2025.117893_bib154","doi-asserted-by":"crossref","first-page":"617","DOI":"10.1097\/00007691-198911000-00001","article-title":"6-mercaptopurine plasma levels in children with acute lymphoblastic leukemia: relation to relapse risk and myelotoxicity","volume":"11","author":"Hayder","year":"1989","journal-title":"Ther. Drug Monit."},{"key":"10.1016\/j.biopha.2025.117893_bib155","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1056\/NEJM199007053230104","article-title":"Systemic exposure to mercaptopurine as a prognostic factor in acute lymphocytic leukemia in children","volume":"323","author":"Koren","year":"1990","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.biopha.2025.117893_bib156","doi-asserted-by":"crossref","first-page":"3569","DOI":"10.1182\/blood.V92.10.3569","article-title":"Pharmacokinetics and pharmacodynamics of oral methotrexate and mercaptopurine in children with lower risk acute lymphoblastic leukemia: a joint children\u2019s cancer group and pediatric oncology branch study","volume":"92","author":"Balis","year":"1998","journal-title":"Blood"},{"key":"10.1016\/j.biopha.2025.117893_bib157","doi-asserted-by":"crossref","first-page":"3476","DOI":"10.1002\/art.38865","article-title":"Folate depletion and increased glutamation in juvenile idiopathic arthritis patients treated with methotrexate","volume":"66","author":"Funk","year":"2014","journal-title":"Arthritis Rheumatol."},{"key":"10.1016\/j.biopha.2025.117893_bib158","doi-asserted-by":"crossref","first-page":"486","DOI":"10.2119\/molmed.2010.00243","article-title":"GNMT expression increases hepatic folate contents and folate-dependent methionine synthase-mediated homocysteine remethylation","volume":"17","author":"Wang","year":"2011","journal-title":"Mol. Med."},{"key":"10.1016\/j.biopha.2025.117893_bib159","doi-asserted-by":"crossref","first-page":"33273","DOI":"10.1074\/jbc.M405183200","article-title":"Differential protein expression analysis of Leishmania major reveals novel roles for methionine adenosyltransferase and S-adenosylmethionine in methotrexate resistance","volume":"279","author":"Drummelsmith","year":"2004","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.biopha.2025.117893_bib160","unstructured":"Furosemide - Drug Usage Statistics, ClinCalc DrugStats Database, (n.d.). \u3008https:\/\/clincalc.com\/DrugStats\/Drugs\/Furosemide\u3009 (accessed December 16, 2020)."},{"key":"10.1016\/j.biopha.2025.117893_bib161","first-page":"381","article-title":"Furosemide (frusemide). A pharmacokinetic\/pharmacodynamic review (Part I)","volume":"18","author":"Ponto","year":"1990","journal-title":"Clin. Pharm."},{"key":"10.1016\/j.biopha.2025.117893_bib162","doi-asserted-by":"crossref","first-page":"318","DOI":"10.1097\/00007691-199706000-00013","article-title":"Possibilities for therapeutic drug monitoring of azathioprine: 6-thioguanine nucleotide concentrations and thiopurine methyltransferase activity in red blood cells","volume":"19","author":"Bergan","year":"1997","journal-title":"Ther. Drug Monit."},{"key":"10.1016\/j.biopha.2025.117893_bib163","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1111\/j.1365-2125.1980.tb01753.x","article-title":"Bioavailability of naproxen sodium and its relationship to clinical analgesic effects","volume":"10","author":"Sevelius","year":"1980","journal-title":"Br. J. Clin. Pharm."},{"key":"10.1016\/j.biopha.2025.117893_bib164","doi-asserted-by":"crossref","first-page":"437","DOI":"10.1007\/s40264-015-0281-0","article-title":"Epidemiology of adverse drug reactions in Europe: a review of recent observational studies","volume":"38","author":"Bouvy","year":"2015","journal-title":"Drug Saf."},{"key":"10.1016\/j.biopha.2025.117893_bib165","doi-asserted-by":"crossref","first-page":"11","DOI":"10.5217\/ir.2020.00155","article-title":"Use of thiopurines in inflammatory bowel disease: an update","volume":"20","author":"Singh","year":"2022","journal-title":"Intest Res"},{"key":"10.1016\/j.biopha.2025.117893_bib166","doi-asserted-by":"crossref","first-page":"e114","DOI":"10.1093\/ibd\/izab102","article-title":"Azathioprine-induced myelotoxicity after switching mesalazine compound","volume":"27","author":"Barnhoorn","year":"2021","journal-title":"Inflamm. Bowel Dis."}],"container-title":["Biomedicine &amp; Pharmacotherapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0753332225000873?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0753332225000873?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,3,3]],"date-time":"2025-03-03T23:44:46Z","timestamp":1741045486000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0753332225000873"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,3]]},"references-count":166,"alternative-id":["S0753332225000873"],"URL":"https:\/\/doi.org\/10.1016\/j.biopha.2025.117893","relation":{},"ISSN":["0753-3322"],"issn-type":[{"value":"0753-3322","type":"print"}],"subject":[],"published":{"date-parts":[[2025,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Thiopurine S-methyltransferase \u2013 An important intersection of drug-drug interactions in thiopurine treatment","name":"articletitle","label":"Article Title"},{"value":"Biomedicine & Pharmacotherapy","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.biopha.2025.117893","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 The Author(s). Published by Elsevier Masson SAS.","name":"copyright","label":"Copyright"}],"article-number":"117893"}}